Drug Database · Clinicians

Orlistat

Brands (23) Lesofat, Ambifit-120, Dr. Trim…Show all

Intestinal Lipase Inhibitor (Lipase Inhibitors) US FDA class
Anti-obesity agent (peripherally acting anti-obesity products); Anti-obesity (peripherally acting); and others PH FDA category

Rx · Prescription drugOTC · Over-the-counter30 PH products
Dispensing: Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 6240792b-9224-2d10-e053-2a91aa0a2c3e, version date September 30, 2026 (Xenical · H2-Pharma LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • XENICAL is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: adults and pediatric patients aged 12 years and…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE XENICAL is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: adults and pediatric patients aged 12 years and older with obesity. adults with overweight in the presence of at least one weight-related comorbid condition. XENICAL is an intestinal lipase inhibitor indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: (1) adults and pediatric patients aged 12 years and older with obesity. adults with overweight in the presence of at least one weight-related comorbid condition.

Contraindications

4 CONTRAINDICATIONS XENICAL is contraindicated in patients with: chronic malabsorption syndrome [see Warnings and Precautions (5.1)] cholestasis known hypersensitivity to orlistat or any of the inactive ingredients in XENICAL. Serious hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported with XENICAL [see Adverse Reactions (6.2)]. Chronic malabsorption syndrome (4) Cholestasis (4) Known hypersensitivity to orlistat or any of the inactive ingredients in XENICAL (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

2 DOSAGE AND ADMINISTRATION The recommended dosage of XENICAL is one 120 mg capsule taken orally three times a day with each main meal containing fat (during or up to 1 hour after the meal). (2) Take XENICAL with a nutritionally balanced, reduced-calorie diet that contains approximately 30% of calories from fat. (2) Distribute the daily intake of fat, carbohydrate, and protein over three main meals.

(2) Skip the dose of XENICAL if a meal is missed or contains no fat. Resume XENICAL at the next scheduled main meal containing fat. (2) Administer a multivitamin containing fat-soluble vitamins once daily at least 2 hours before or 2 hours after administration of XENICAL, or at bedtime. (2) Recommended Dosage and Administration The recommended dosage of XENICAL is one 120 mg capsule taken orally three times a day with each main meal containing fat (during or up to 1 hour after the meal).

Dosages above 120 mg three times a day have not been shown to provide additional benefit. Take XENICAL with a nutritionally balanced, reduced-calorie diet that contains approximately 30% of calories from fat [see Warnings and Precautions (5.5) and Clinical Studies (14.1)]. Distribute the daily intake of fat, carbohydrate, and protein over three main meals.

Skip the dose of XENICAL if a meal is missed or contains no fat. Resume XENICAL at the next scheduled main meal containing fat. Administer a multivitamin containing fat-soluble vitamins once daily at least 2 hours before or 2 hours after administration of XENICAL, or at bedtime [see Warnings and Precautions (5.1) and Drug Interactions (7)].

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of XENICAL in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term have been established in pediatric patients aged 12 years and older with obesity. Use of XENICAL in this indication is supported by a 54-week randomized, placebo-controlled trial in 539 pediatric patients aged 12 years and older with obesity (defined as a baseline BMI that was 2 units greater than the US weighted mean for the 95 th percentile based on age and sex) [see Clinical Pharmacology (12.2), Clinical Studies (14.2)] and from trials in adult patients with obesity [see Clinical Studies (14.1)].

Adverse reactions with XENICAL treatment in pediatric patients aged 12 years and older were generally similar to those reported in adults [see Adverse Reactions (6.1)]. The safety and effectiveness of XENICAL have not been established in pediatric patients less than 12 years of age.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Clinical studies of XENICAL did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients [see Clinical Studies (14.1)].

Dosage forms

Philippines

  • Capsule: 60 mg, 120 mg
  • Hard gelatin capsule: 120 mg

Registered products in the Philippines

30 products registered with the Food and Drug Administration (FDA) Philippines list Orlistat as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products30
Philippine FDA-registered products for Orlistat
Package insert
Ambifit-120Orlistat
120 mg CapsuleAlu/Alu Blister Pack x 10’s Box of 30’s
OTC
Zim Laboratories LimitedIndia
Importer: Ambica International Corporation
DRP-8021
Nov 16, 2028
Dr. TrimOrlistat
60 mg CapsuleAlu/Clear PVC Blister Pack with Tropical Foil x 10's (Box of 10's and 30's)
Rx
PHIL. UNITED PHARMA CORPORATIONPhilippines
Trader: DOCTEUR'S CHOICE CORPORATION
DRP-8542
Nov 5, 2029
Dr. Trim 120Orlistat
120 mg CapsuleAlu/Clear PVC Blister Pack with Tropical Foil x 10's (Box of 10's and 30's)
OTC
Phil. United Pharma Corp.Philippines
Trader: Docteur's Choice Corporation
DRP-8544
Nov 5, 2029
FatrimOrlistat
120 mg CapsuleAlu / Clear PVC Blister Pack x 10's (Box of 20's)
Rx
Scheele Laboratories Phils., Inc.Philippines
—
DRP-6534
Feb 22, 2031
LesofatOrlistat
120 mg CapsuleBlister Pack x 20's (Box of 20's)
OTC
Lloyd Laboratories, Inc.Philippines
Dr. Zen’s Research, Inc.Trader: Euro-Health Care Exponents, Inc.
DR-XY33456
Jun 7, 2027
LesofatOrlistat
60 mg CapsuleAlu/ PVC Blister Pack x 20's in a Box
OTC
Lloyd Laboratories, Inc.Philippines
Dr. Zen’s Research, Inc.Trader: Euro-Health Care Exponents, Inc.
DR-XY35231
Dec 15, 2028
LifedietOrlistat
60 mg CapsuleAlu/PVC Blister Pack x 10's & 20's (Box of 20's)
OTC
Flourish PharmaIndia
Biophil Medical Equipment And Supplies Trading
DRP-17911
Apr 7, 2031
ListalifeOrlistat
120 mg CapsuleAlu/PVC Blister Pack x 10's & 20's (Box of 20's)
OTC
Flourish PharmaIndia
Biophil Medical Equipment and Supplies Trading
DRP-16717
Jun 26, 2030
NoneOrlistat
120 mg CapsuleAlu/PVC Blister Pack x 20's (Box of 20's)
OTC
Lloyd Laboratories, Inc.Philippines
Innogen Pharmaceuticals, Inc.Trader: Dr. Zen’s Research, Inc.
DR-XY46846
Mar 25, 2030
NoneOrlistat
120 mg CapsuleAlu/PVC Blister Pack x 20's (Box of 20's)
OTC
Lloyd Laboratories, Inc.Philippines
Innogen Pharmaceuticals, Inc.Trader: Dr. Zen’s Research, Inc.
DRP-16373
Mar 25, 2030
NoneOrlistat
120 mg CapsuleAlu/Alu Strip Foil x 4's (Box of 24's)
Rx
Pascual Laboratories, Inc.Philippines
Pharex Health Corporation
DRP-5938
Aug 22, 2031
NoneOrlistat
120 mg CapsuleAlu/Clear PVC Blister Pack with Tropical Foil x 10's (Box of 10's and 30's)
OTC
Phil. United Pharma CorporationPhilippines
—
DRP-8083
Jan 25, 2029
NoneOrlistat
60mg CapsuleAlu/Clear PVC Blister Pack with Tropical Foil x 10's Box of 10's; Alu/Clear PVC Blister Pack with Tropical Foil x 10's Box of 30's
OTC
Phil. United Pharma CorporationPhilippines
—
DRP-8082
Jan 25, 2029
Novastat 120Orlistat
120 mg CapsuleAlu-Alu Blister Pack x 15's (Box of 30's)
OTC
Acme Generics LLP.India
Medinova Pharmaceutical Inc.Trader: n/A
DRP-11482
Mar 16, 2027
Novastat 60Orlistat
60 mg CapsuleAlu-Alu Blister Pack x 15's (Box of 30's)
OTC
Acme Generics LLP.India
Medinova Pharmaceutical Inc.
DRP-11337
Mar 3, 2027
OrlicinOrlistat
60 mg CapsuleAlu/Clear PVC Blister Pack with Tropical Foil x 10's (Box of 10's and 30's)
OTC
Phil. United Pharma Corp.Philippines
Trader: Golden Dale Pharma Corp.
DRP-8543
Nov 5, 2029
Orlicin 120Orlistat
120 mg CapsuleAlu/Clear PVC Blister Pack with Tropical Foil x 10's (Box of 10's and 30's)
OTC
Phil. United Pharma CorporationPhilippines
Trader: Golden Dale Pharma Corp.
DRP-8545
Nov 5, 2029
OrlifastOrlistat
60 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Innogen Pharmaceuticals, Inc.Trader: Dr. Zen’s Research, Inc.
DRP-9448
May 14, 2030
OrlisOrlistat
120 mg CapsuleAlu/Alu blister Pack x 5's (Box of 30's)
Rx
Ferozsons Laboratories LimitedPakistan
First Global Trading Corporation
DR-XY44738
Aug 11, 2031
OrlislimOrlistat
120 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
OTC
XL LABORATORIES PVT. LTD.India
Ambica International Corporation
DRP-3336
Oct 25, 2031
OrslimOrlistat
120 mg Hard Gelatin CapsuleAlu-Alu Blister Pack x 10's Box of 30's and 90's; Alu-Alu Blister Pack x 1's (as physician sample) Box of 1's
OTC
PharmEvo (Pvt.) Ltd.Pakistan
Accesspoint International Trading Inc.
DR-XY43368
Apr 28, 2029
RedoXfat PlusOrlistat
120 mg CapsuleAluminum Foil/PVC film clear blister (with tropical foil) x 10's (Box of 30's)
OTC
Phil. United Pharma CorporationPhilippines
ATC Healthcare International Corp.
DRP-7260
Jul 11, 2027
RedoXfat Plus 60Orlistat
60 mg CapsuleAluminum foil/PVC film clear blister pack (with tropical foil) x 10’s (Box of 30’s)
OTC
Phil. United Pharma CorporationPhilippines
ATC Healthcare International Corp.
DRP-7465
Nov 16, 2027
SydenslimOrlistat
120 mg CapsuleAlu/PVDC White Opaque Blister x 10's (Box of 30's)
OTC
Sydenham Laboratories, Inc.Philippines
—
DRP-12491
Aug 19, 2027
SyreduceOrlistat
120 mg CapsuleAlu/PVDC White Opaque Blister Pack x 10's (Box of 30's)
OTC
Sydenham Laboratories, Inc.Philippines
Sydenham Pharmaceuticals, Inc.
DRP-12630
Sep 22, 2027
The Diet Coach BellaOrlistat
120 mg CapsuleAlu-PVC/PVDC Blister Pack x 21's (Box of 21's and 84's)
Rx
Fredun Pharmaceuticals LimitedIndia
PhilRx Pharma Inc.
DRP-9100
Aug 5, 2030
UnbrandedOrlistat
120 mg CapsuleAlu/Alu Strip Foil x 4's (Box of 24's)
OTC
Pascual Laboratories, Inc.Philippines
Watsons Personal Care Stores (Philippines), Inc.
DRP-5938-01
Aug 22, 2031
XenicalOrlistat
120 mg CapsuleAlu/PVC-PVDC Blister Pack x 21's (Box of 21's)
OTC
Delpharm Milano S.r.l.Italy
Zuellig Pharma Corporation
DRP-527
May 23, 2028
XenistaOrlistat
120 mg CapsuleAlu-Clear PVC Blister Pack x 10's (Box of 10's)
OTC
Geofman PharmaceuticalsPakistan
Sahar International Trading Inc.
DR-XY40548
Jan 18, 2027
XiomicOrlistat
120 mg CapsuleAlu-PVC/PVDC Blister Pack x 21’s Box of 21’s
OTC
Kanion Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-8695
Feb 5, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Capsules: 120 mg, turquoise, imprinted with “XENICAL 120” in black ink. Capsules: 120 mg. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Loss of Effect of Certain Medications and Dietary Supplements with Coadministration of XENICAL: Serious outcomes due to the loss of effect of cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene have been reported with coadministration of XENICAL. (5.1)
  • Liver Injury: Severe liver injury with hepatocellular necrosis or acute hepatic failure have been reported in patients treated with XENICAL, some cases resulted in liver transplant or death. Instruct patients to report any symptoms of hepatic dysfunction, immediately discontinue if symptoms occur and obtain liver function tests. (5.2)
  • Oxalate Nephrolithiasis and Oxalate Nephropathy with Renal Failure: Monitor renal function in patients at increased risk for oxalate nephropathy. Discontinue XENICAL in patients who develop oxalate nephropathy. (5.3)
  • Acute Gallbladder Disease: Has occurred in clinical trials and in postmarketing. If suspected, gallbladder studies and appropriate clinical follow-up are indicated. (5.4)
  • Gastrointestinal Events: May increase when XENICAL is taken with a diet high in fat (>30% total daily calories from fat). Advise patients to adhere to dietary guidelines and distribute the daily intake of fat over three main meals. (5.5)
5.1 Loss of Effect of Certain Medications and Dietary Supplements with Coadministration

5.1 Loss of Effect of Certain Medications and Dietary Supplements with Coadministration of XENICAL Serious outcomes due to the loss of effect of cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene have been reported with coadministration of XENICAL. Do not coadminister XENICAL simultaneously with cyclosporine or levothyroxine [see Drug Interactions (7)].

Administer cyclosporine 3 hours after the administration of XENICAL. Administer levothyroxine and XENICAL at least 4 hours apart. Administer a multivitamin supplement at least 2 hours before or 2 hours after the administration of XENICAL, or at bedtime. Monitor the effectiveness of cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene, as clinically indicated [see Drug Interactions (7) and Clinical Pharmacology (12.3)].

5.2 Liver Injury

5.2 Liver Injury There have been rare postmarketing reports of severe liver injury with hepatocellular necrosis or acute hepatic failure in patients treated with XENICAL, with some of these cases resulting in liver transplant or death [see Adverse Reactions (6.2)]. Instruct patients to report any symptoms of hepatic dysfunction (anorexia, pruritus, jaundice, dark urine, light-colored stools, or right upper quadrant pain) while taking XENICAL.

When these symptoms occur, immediately discontinue XENICAL and other suspected medications and obtain liver function tests, including ALT and AST levels.

5.3 Oxalate Nephrolithiasis

5.3 Oxalate Nephrolithiasis and Oxalate Nephropathy with Renal Failure XENICAL may increase levels of urinary oxalate. Cases of oxalate nephrolithiasis and oxalate nephropathy with renal failure have been reported [see Adverse Reactions (6.2)]. Monitor renal function when prescribing XENICAL to patients at increased risk for oxalate nephropathy, including patients with renal impairment and in those with a history of hyperoxaluria or calcium oxalate nephrolithiasis.

Discontinue XENICAL in patients who develop oxalate nephropathy.

5.4 Acute Gallbladder Disease

5.4 Acute Gallbladder Disease Acute events of gallbladder disease such as cholelithiasis, have been reported in clinical trials and during the postmarketing experience with XENICAL. In a 4-year clinical trial of XENICAL, cholelithiasis was reported in 2.9% (47/1649) of XENICAL-treated patients versus 1.8% (30/1655) of placebo-treated patients.

If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.

5.5 Gastrointestinal Events

5.5 Gastrointestinal Events Gastrointestinal events may increase when XENICAL is taken with a diet high in fat (>30% total daily calories from fat) [see Adverse Reactions (6.1)]. Advise patients receiving XENICAL to adhere to dietary guidelines [see Dosage and Administration (2)]. The daily intake of fat should be distributed over three main meals.

If XENICAL is taken with any one meal very high in fat, the possibility of gastrointestinal effects increases.

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Cyclosporine: Avoid simultaneous coadministration with XENICAL. Administer cyclosporine 3 hours after XENICAL. Monitor for effectiveness. (7) Fat-soluble Vitamin Supplements and Analogues: Administer a multivitamin supplement at least 2 hours before or 2 hours after the administration of XENICAL, or at bedtime.

(7) Levothyroxine: Avoid simultaneous coadministration with XENICAL. Administer levothyroxine and XENICAL at least 4 hours apart. Monitor for changes in thyroid function. (7) Anticoagulants including Warfarin: Monitor for changes in coagulation parameters. (7) Amiodarone: Monitor patients as clinically indicated. (7) Antiepileptic Drugs: Monitor patients for changes in seizure frequency.

(7) Antiretroviral Drugs: Monitor HIV RNA levels frequently and discontinue XENICAL if there is an increase in HIV viral load. (7) Table 4 describes the clinically significant drug and dietary supplement interactions with XENICAL. Table 4 Clinically Significant Drug and Dietary Supplement Interactions with XENICAL Cyclosporine Clinical Impact Coadministration of XENICAL and cyclosporine reduces cyclosporine plasma levels [see Clinical Pharmacology (12.3)].

Intervention Avoid simultaneous coadministration of XENICAL and cyclosporine. Administer cyclosporine 3 hours after the administration of XENICAL. In those patients whose cyclosporine levels are being measured, monitor more frequently [see Warnings and Precautions (5.1)]. Fat-soluble Vitamin Supplements and Analogues Clinical Impact The absorption of beta-carotene supplements is reduced when concomitantly administered with XENICAL.

XENICAL also inhibited absorption of a vitamin E acetate supplement. The effect of XENICAL on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known [see Clinical Pharmacology (12.3) and Warnings and Precautions (5.1)]. Intervention Administer a multivitamin supplement at least 2 hours before or 2 hours after the administration of XENICAL, or at bedtime [see Dosage and Administration (2)].

Levothyroxine Clinical Impact Hypothyroidism has been reported in patients treated concomitantly with XENICAL and levothyroxine postmarketing. Intervention Avoid simultaneous coadministration of XENICAL and levothyroxine. Administer levothyroxine and XENICAL at least 4 hours apart [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

Monitor patients treated concomitantly with XENICAL and levothyroxine for changes in thyroid function. Anticoagulants including Warfarin Clinical Impact Vitamin K absorption may be decreased with XENICAL. Reports of decreased prothrombin, increased INR and unbalanced anticoagulant treatment resulting in change of hemostatic parameters have been reported in patients treated concomitantly with XENICAL and anticoagulants.

Intervention Monitor patients on warfarin or other anticoagulants who are prescribed XENICAL for changes in coagulation parameters [see Clinical Pharmacology (12.3)]. Amiodarone Clinical Impact Coadministration of XENICAL and amiodarone reduces exposure to amiodarone and its metabolite, desethylamiodarone [see Clinical Pharmacology (12.3)].

A reduced therapeutic effect of amiodarone is possible. The effect of commencing orlistat treatment in patients on stable amiodarone therapy has not been studied. Intervention Monitor patients as clinically indicated. Antiepileptic Drugs Clinical Impact XENICAL may decrease the effect of antiepileptic drugs. Convulsions have been reported in patients treated concomitantly with orlistat and antiepileptic drugs.

Intervention Monitor patients for changes in seizure frequency. Antiretroviral Drugs Clinical Impact Loss of virological control has been reported in HIV-infected patients taking orlistat concomitantly with antiretroviral drugs such as atazanavir, ritonavir, tenofovir disoproxil fumarate, emtricitabine, and with the combinations lopinavir/ritonavir and emtricitabine/efavirenz/tenofovir disoproxil fumarate.

The exact mechanism for this is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Intervention HIV RNA levels should be frequently monitored in patients who take XENICAL while being treated for HIV infection. Discontinue XENICAL if there is a confirmed increase in HIV viral load.

Adverse reactions

Adverse reactions (US label) US FDA label
  • Most common treatment emergent adverse reactions (≥5% and at least twice that of placebo) include oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation and fecal incontinence. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact the Safety Call Center at 1-888-236-5445 or FDA at 1‑800‑FDA‑1088 (1-800-332-1088) or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in patients. Most Commonly Observed Adverse Reactions during 1 Year of Treatment XENICAL was evaluated for safety in adults with obesity or overweight with at least one comorbid condition in seven multicenter, double-blind, placebo-controlled clinical trials of 1- to 2-years duration, and in a 4-year trial.

The seven trials included 1,466 patients treated with placebo, 1,913 patients treated with XENICAL 120 mg orally three times a day, and 809 patients treated with unapproved dosages of XENICAL. Age of the patients ranged from 17 to 78 years; 80% were female, 91% White, 6% Black or African American, 2% were of Hispanic or Latino ethnicity, and 1% of other races.

Six of the trials enrolled patients without type 2 diabetes mellitus (Trials 1-6) and one of the trials enrolled a population of patients with type 2 diabetes mellitus (Trial 7). The 4-year trial (Trial 8) included 3,304 patients, age range 30-58 years; 55% were female; 99% were White and 1% other races. This trial included a subset of patients with abnormal glucose at baseline [see Clinical Studies (14.1)].

In placebo-controlled clinical trials, 9% of patients treated with XENICAL discontinued treatment due to adverse reactions, compared with 5% of placebo-treated patients. The most common adverse reactions that led to discontinuation of XENICAL treatment were gastrointestinal in nature. Gastrointestinal symptoms, as shown in Table 1, were the most commonly observed adverse reactions associated with the use of XENICAL in the first year of seven placebo-controlled clinical trials.

In general, the first occurrence of these events was within 3 months of starting therapy. Table 1 Adverse Reactions (5% and an incidence at least twice that of placebo) in XENICAL-Treated Adults with Obesity or Overweight for Chronic Weight Management During 1 Year of Treatment Adverse Event Placebo % Patients (N=1,466) XENICAL % Patients (N=1,913) Oily Spotting a 1 27 Flatus with Discharge 1 24 Fecal Urgency 7 22 Fatty/Oily Stool a 3 20 Oily Evacuation a 1 12 Increased Defecation 4 11 Fecal Incontinence 1 8 a Oily discharge may be clear or have a coloration such as orange or brown.

Table 2 lists other adverse reactions from the seven placebo-controlled clinical trials that occurred at a frequency of ≥3% among patients treated with XENICAL and with an incidence that was greater than placebo during year 1. Table 2 Adverse Reactions (incidence ≥3% and greater than placebo) from Seven Placebo-Controlled Clinical Trials During 1 Year of Treatment Adverse Event Placebo % Patients (N=1,466) XENICAL % Patients (N=1,913) Influenza 36 40 Upper Respiratory Infection 33 38 Headache 28 31 Abdominal Pain/Discomfort 21 26 Back Pain 12 14 Menstrual Irregularity 8 10 Lower Respiratory Infection 7 8 Nausea 7 8 Urinary Tract Infection 7 8 Fatigue 6 7 Arthritis 5 5 Dizziness 5 5 Anxiety 3 5 Infectious Diarrhea 4 5 Rectal Pain/Discomfort 4 5 Vaginitis 4 4 Rash 4 4 Vomiting 4 4 Otitis 3 4 Sleep Disorders 3 4 Myalgia 3 4 Tooth Disorder 3 4 Gingival Disorder 3 4 Other Adverse Reactions Low Vitamin Levels Table 3 illustrates the percentage of adult patients on XENICAL and placebo who developed a low blood vitamin level on two or more consecutive visits in studies up to 2 years in which patients were not previously receiving vitamin supplementation.

Table 3 Incidence of Low Blood Vitamin Values on Two or More Consecutive Visits (Adult Patients with Normal Nonsupplemented Baseline Values) Placebo % Patients XENICAL % Patients Vitamin D 7 12 Beta-carotene 2 6 Vitamin E 1 6 Vitamin A 1 2 Adverse Reactions in Patients with Type 2 Diabetes Mellitus Hypoglycemia and abdominal distension were also reported in clinical trials in patients with type 2 diabetes mellitus and overweight or obesity. Adverse Reactions in Pediatric Patients Aged 12 Years and Older with Obesity In clinical trials with XENICAL in pediatric patients aged 12 years and older with obesity, adverse reactions were similar to those reported in adults [see Clinical Studies (14.2)].

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of XENICAL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to XENICAL exposure.

Immune System: Rare cases of hypersensitivity. Signs and symptoms have included pruritus, rash, urticaria, angioedema, bronchospasm and anaphylaxis. Very rare cases of bullous eruption. Gastrointestinal: Pancreatitis; lower gastrointestinal bleeding. Hepatobiliary: Hepatitis that may be serious, and hepatic failure, with some of these cases resulting in liver transplant or death [see Warnings and Precautions (5.2)]; cholelithiasis [see Warnings and Precautions (5.4)]; increases in transaminases and alkaline phosphatase.

Skin and Subcutaneous Tissue: Leukocytoclastic vasculitis. Clinical signs include palpable purpura, maculopapular lesions, or bullous eruption. Renal and Urinary: Acute oxalate nephropathy and hyperoxaluria in patients with or at risk for renal disease.

Adverse reaction frequency tables (US label) US FDA label
Adverse Event Placebo % Patients (N=1,466) XENICAL % Patients (N=1,913)
Oily Spottinga 1 27
Flatus with Discharge 1 24
Fecal Urgency 7 22
Fatty/Oily Stoola 3 20
Oily Evacuationa 1 12
Increased Defecation 4 11
Fecal Incontinence 1 8
Adverse Event Placebo % Patients (N=1,466) XENICAL % Patients (N=1,913)
Influenza 36 40
Upper Respiratory Infection 33 38
Headache 28 31
Abdominal Pain/Discomfort 21 26
Back Pain 12 14
Menstrual Irregularity 8 10
Lower Respiratory Infection 7 8
Nausea 7 8
Urinary Tract Infection 7 8
Fatigue 6 7
Arthritis 5 5
Dizziness 5 5
Anxiety 3 5
Infectious Diarrhea 4 5
Rectal Pain/Discomfort 4 5
Vaginitis 4 4
Rash 4 4
Vomiting 4 4
Otitis 3 4
Sleep Disorders 3 4
Myalgia 3 4
Tooth Disorder 3 4
Gingival Disorder 3 4
Placebo % Patients XENICAL % Patients
Vitamin D 7 12
Beta-carotene 2 6
Vitamin E 1 6
Vitamin A 1 2

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Available data from published prospective and retrospective cohort studies over decades of use with XENICAL during pregnancy have not identified an increased risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. However, weight loss offers no benefit to a pregnant patient and may result in a small for gestational age infant.

When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus and discontinue XENICAL (see Clinical Considerations). Oral administration of orlistat to pregnant rats and rabbits during the period of organogenesis did not show any adverse embryofetal effects at doses 23 times and 47 times, respectively, the maximum recommended human dose (MRHD) based on body surface area (mg/m 2) (see Data).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Appropriate weight gain based on pre-pregnancy weight is currently recommended for all pregnant patients, including those who have overweight or obesity, because of the obligatory weight gain that occurs in maternal tissues during pregnancy. Data Animal Data In embryofetal development studies in pregnant rats and rabbits administered orlistat during organogenesis, no adverse embryofetal effects were seen at doses up to 800 mg/kg/day, corresponding to 23 times and 47 times MRHD, respectively based on body surface area (mg/m 2).

In a pre- and post-natal development study in pregnant rats dosed orlistat during gestation through lactation, no adverse developmental effects were observed in the offspring at doses up to 400 mg/kg/day, corresponding to 12 times MRHD, based on body surface area (mg/m 2).

Risk Summary Available data from published prospective and retrospective cohort studies over decades of use with XENICAL during pregnancy have not identified an increased risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. However, weight loss offers no benefit to a pregnant patient and may result in a small for gestational age infant.

When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus and discontinue XENICAL (see Clinical Considerations). Oral administration of orlistat to pregnant rats and rabbits during the period of organogenesis did not show any adverse embryofetal effects at doses 23 times and 47 times, respectively, the maximum recommended human dose (MRHD) based on body surface area (mg/m 2) (see Data).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Appropriate weight gain based on pre-pregnancy weight is currently recommended for all pregnant patients, including those who have overweight or obesity, because of the obligatory weight gain that occurs in maternal tissues during pregnancy. Data Animal Data In embryofetal development studies in pregnant rats and rabbits administered orlistat during organogenesis, no adverse embryofetal effects were seen at doses up to 800 mg/kg/day, corresponding to 23 times and 47 times MRHD, respectively based on body surface area (mg/m 2).

In a pre- and post-natal development study in pregnant rats dosed orlistat during gestation through lactation, no adverse developmental effects were observed in the offspring at doses up to 400 mg/kg/day, corresponding to 12 times MRHD, based on body surface area (mg/m 2).

Mechanism of action

12.1 Mechanism of Action Orlistat is a reversible inhibitor of gastrointestinal lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The inactivated enzymes are thus unavailable to hydrolyze dietary fat in the form of triglycerides into absorbable free fatty acids and monoglycerides. Undigested triglycerides are not absorbed, resulting in a caloric deficit.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Dose-response Relationship The dose-response relationship for orlistat in adult human volunteers is shown in Figure 1. The effect is the percentage of ingested fat excreted, referred to as fecal fat excretion percentage. Both individual data (open circles) and the curve predicted for the population with the maximum-effect model (continuous line) are shown in Figure 1.

Figure 1 Dose-Response Relationship for Orlistat in Adult Human Volunteers At the recommended therapeutic dose of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30% in adult patients. Orlistat-treated pediatric patients excreted more fecal fat daily (27% of dietary intake) than placebo-treated pediatric patients (7% of dietary intake).

The magnitude of fecal fat excretion was consistent with that in adults (approximately 30%). Ethanol does not affect orlistat’s effect on preventing the absorption of fat. Based on fecal fat measurements, the effect of orlistat is seen as soon as 24 to 48 hours after dosing. Upon discontinuation of therapy, fecal fat content usually returns to pretreatment levels within 48 to 72 hours.

Other Short-term Studies Adult Patients In several studies of up to 6-weeks duration, the effects of therapeutic doses of orlistat on gastrointestinal and systemic physiological processes were assessed in subjects with normal weight and with obesity. Postprandial cholecystokinin plasma concentrations were lowered after multiple doses of orlistat in two studies but not significantly different from placebo in two other experiments.

There were no clinically significant changes observed in gallbladder motility, bile composition or lithogenicity, or colonic cell proliferation rate, and no clinically significant reduction of gastric emptying time or gastric acidity. In addition, no effects on plasma triglyceride levels or systemic lipases were observed with the administration of orlistat in these studies.

In a 3-week study of 28 healthy male volunteers, orlistat (120 mg three times a day) did not significantly affect the balance of calcium, magnesium, phosphorus, zinc, copper, and iron. Pediatric Patients In a 3-week study of 32 pediatric patients aged 12 years and older with obesity, orlistat (120 mg three times a day) did not significantly affect the balance of calcium, magnesium, phosphorus, zinc, or copper.

The iron balance was decreased by 64.7 µmole/24 hours and 40.4 µmole/24 hours in orlistat and placebo treatment groups, respectively. Compared to placebo, orlistat lowers BMI with greater fat mass loss than lean mass loss in pediatric patients. Figure 1

Dose-response Relationship The dose-response relationship for orlistat in adult human volunteers is shown in Figure 1. The effect is the percentage of ingested fat excreted, referred to as fecal fat excretion percentage. Both individual data (open circles) and the curve predicted for the population with the maximum-effect model (continuous line) are shown in Figure 1.

Figure 1 Dose-Response Relationship for Orlistat in Adult Human Volunteers At the recommended therapeutic dose of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30% in adult patients. Orlistat-treated pediatric patients excreted more fecal fat daily (27% of dietary intake) than placebo-treated pediatric patients (7% of dietary intake).

The magnitude of fecal fat excretion was consistent with that in adults (approximately 30%). Ethanol does not affect orlistat’s effect on preventing the absorption of fat. Based on fecal fat measurements, the effect of orlistat is seen as soon as 24 to 48 hours after dosing. Upon discontinuation of therapy, fecal fat content usually returns to pretreatment levels within 48 to 72 hours.

Other Short-term Studies Adult Patients In several studies of up to 6-weeks duration, the effects of therapeutic doses of orlistat on gastrointestinal and systemic physiological processes were assessed in subjects with normal weight and with obesity. Postprandial cholecystokinin plasma concentrations were lowered after multiple doses of orlistat in two studies but not significantly different from placebo in two other experiments.

There were no clinically significant changes observed in gallbladder motility, bile composition or lithogenicity, or colonic cell proliferation rate, and no clinically significant reduction of gastric emptying time or gastric acidity. In addition, no effects on plasma triglyceride levels or systemic lipases were observed with the administration of orlistat in these studies.

In a 3-week study of 28 healthy male volunteers, orlistat (120 mg three times a day) did not significantly affect the balance of calcium, magnesium, phosphorus, zinc, copper, and iron. Pediatric Patients In a 3-week study of 32 pediatric patients aged 12 years and older with obesity, orlistat (120 mg three times a day) did not significantly affect the balance of calcium, magnesium, phosphorus, zinc, or copper.

The iron balance was decreased by 64.7 µmole/24 hours and 40.4 µmole/24 hours in orlistat and placebo treatment groups, respectively. Compared to placebo, orlistat lowers BMI with greater fat mass loss than lean mass loss in pediatric patients. Figure 1

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The primary metabolite M1 had a short half-life (approximately 3 hours) whereas the secondary metabolite M3 eliminated at a slower rate (half-life approximately 13.5 hours).

Excretion Following a single oral dose of 360 mg 14 C-orlistat in subjects with normal weight and with obesity, fecal excretion of the unabsorbed drug was found to be the major route of elimination.

Orlistat and its M1 and M3 metabolites were also subject to biliary excretion.

Approximately 97% of the administered radioactivity was excreted in feces; 83% of that was found to be unchanged orlistat.

The cumulative renal excretion of total radioactivity was <2% of the given dose of 360 mg 14 C-orlistat.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption Systemic exposure to orlistat is minimal. Following oral dosing with 360 mg 14 C-orlistat, plasma radioactivity peaked at approximately 8 hours; plasma concentrations of intact orlistat were near the limits of detection (<5 ng/mL). In therapeutic studies involving monitoring of plasma samples, detection of intact orlistat in plasma was sporadic and concentrations were low (<10 ng/mL or 0.02 µM), without evidence of accumulation, and consistent with minimal absorption.

Distribution In vitro orlistat was >99% bound to plasma proteins (lipoproteins and albumin were major binding proteins). Orlistat minimally partitioned into erythrocytes. Elimination Metabolism Based on an oral 14 C-orlistat mass balance study in patients with obesity, two metabolites, M1 (the hydrolyzed ß-lactone ring product of orlistat) and M3 (sequential metabolite after M1’s cleavage of the N-formyl leucine side-chain), accounted for approximately 42% of total radioactivity in plasma.

M1 and M3 have an open ß-lactone ring and extremely weak lipase inhibitory activity (1000- and 2500-fold less than orlistat, respectively). In view of this low inhibitory activity and the low plasma levels at the therapeutic dose (average of 26 ng/mL and 108 ng/mL for M1 and M3, respectively, 2 to 4 hours after a dose), these metabolites are considered pharmacologically inconsequential.

The primary metabolite M1 had a short half-life (approximately 3 hours) whereas the secondary metabolite M3 eliminated at a slower rate (half-life approximately 13.5 hours). Plasma concentrations of orlistat and its metabolites M1 and M3 were similar in pediatric patients to those found in adults at the same dose level.

Excretion Following a single oral dose of 360 mg 14 C-orlistat in subjects with normal weight and with obesity, fecal excretion of the unabsorbed drug was found to be the major route of elimination. Orlistat and its M1 and M3 metabolites were also subject to biliary excretion. Approximately 97% of the administered radioactivity was excreted in feces; 83% of that was found to be unchanged orlistat.

The cumulative renal excretion of total radioactivity was <2% of the given dose of 360 mg 14 C-orlistat. The time to reach complete excretion (fecal plus urinary) was 3 to 5 days. The disposition of orlistat appeared to be similar between subjects with normal weight and subjects with obesity. Based on limited data, the half-life of the absorbed orlistat is in the range of 1 to 2 hours.

Specific Populations No pharmacokinetic study was conducted for specific populations such as geriatric patients, patients of different races, and patients with renal or hepatic impairment. Drug Interaction Studies Alcohol In a multiple-dose study in 30 normal-weight subjects, coadministration of orlistat and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.

Amiodarone In a pharmacokinetic study conducted in healthy volunteers who received 120 mg orlistat three times daily for 13 days and a single dose of 120 mg orlistat on the morning of Day 14 co-administered with a single dose of 1,200 mg amiodarone on Day 4, a 23 to 27% reduction in the systemic exposure to amiodarone and desethylamiodarone was observed [see Drug Interactions (7)]. The effect of commencing orlistat treatment in patients on stable amiodarone therapy has not been studied.

Cyclosporine In a multiple-dose study, coadministration of 50 mg cyclosporine twice daily with 120 mg orlistat three times daily decreased cyclosporine AUC and C max by 31% and 25%, respectively. In the same study, administration of 50 mg cyclosporine twice daily three hours after the administration of 120 mg orlistat three times daily decreased cyclosporine AUC and C max by 17% and 4%, respectively.

Digoxin In 12 normal-weight subjects receiving orlistat 120 mg three times a day for 6 days, orlistat did not alter the pharmacokinetics of a single dose of digoxin. Fat-soluble Vitamin Supplements and Analogues A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with orlistat.

Orlistat inhibited absorption of a vitamin E acetate supplement by approximately 60%. The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known. Glyburide In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.

Nifedipine (extended-release tablets) In 17 normal-weight subjects receiving orlistat 120 mg three times a day for 6 days, orlistat did not alter the bioavailability of nifedipine (extended-release tablets). Oral Contraceptives In 20 normal-weight female subjects, the treatment of orlistat 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives.

Phenytoin In 12 normal-weight subjects receiving orlistat 120 mg three times a day for 7 days, orlistat did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. Pravastatin In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving orlistat 120 mg three times a day for 6 days, orlistat did not affect the pharmacokinetics of pravastatin.

Warfarin In 12 normal-weight subjects, administration of orlistat 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with orlistat administration, vitamin K levels tended to decline in subjects taking orlistat [see Drug Interactions (7)].

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Xenical · H2-Pharma LLC [US FDA-approved label, version 11, September 30, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6240792b-9224-2d10-e053-2a91aa0a2c3e
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .